An inspiring play about Parkinson’s and Parkour is coming to a theatre near you
Author: Geoffrey ChangPublished: 8 September 2016
Prep: Cook: Serves:
A new thought-provoking play that explores the friendship between a free-running teenager and a woman with early-onset Parkinson’s is going on a nationwide tour
After three sell-out shows in cities across the UK and rave reviews, a new Parkinson’s play called Kinetics is taking to the road for a run of 13 performances throughout September and October.
Based on a true story, the inspiring theatre piece explores the unlikely friendship between a teenage boy who is devoted to free running (Parkour) – the extreme sport that involves navigating obstacles without equipment – and a middle-aged woman with early-onset Parkinson’s disease.
But what can they possibly have in common? Despite living completely opposing lives, a chance encounter leads the two protagonists to realise the answer: they share the desire to move.
Featuring projected imagery and electrifying live Parkour, the show raises awareness of Parkinson’s with wit, while challenging perceptions and giving a realistic insight into the daily struggles that come with living with the condition.
Written by actor and drama teacher, Sue Wylie, the play recounts her personal experience of living with Parkinson’s. Sue, who performs the lead role, explains: “Five years ago shortly after my 50th birthday I was diagnosed with Parkinson’s. After the initial shock I knew I wanted to write about it. I was teaching drama at the time and discovered that a bright but rebellious 16-year-old student in my tutor group was free running on the school roof.
“I was intrigued by the risks he took in his addiction to this extreme sport. How interesting to contrast that with a middle-aged woman whose world of movement is slowly being eroded. What if their paths should accidentally cross and a friendship form? I knew there was a story in there and so Kinetics was born.”
Sue Wylie (left) playing lead character Rose
Through the juxtaposition of the characters the sharp script, full of emotion and humour, unexpectedly draws parallels between two lives that couldn’t seem more opposite. The two learn more important life lessons from one another than they ever could have imagined.
Following the initial success of sold out shows last year, Kinetics received funding from the Arts Council, allowing them to organise the upcoming Autumn 2016 tour. Parkinson’s UK have officially endorsed the play with CEO Steve Ford saying: “Sue’s play offers an inspiring story to which we can all relate.”
Robin Buttery: the man behind the 3,600-mile Indian Ocean row
4 days ago
Parkinson’s gene therapy could improve motor symptoms
UK researchers are trialling an innovative gene therapy that could improve motor symptoms – such as tremors and rigidity – experienced by people with Parkinson’s. The therapy, named AXO-Lenti-PD, has been developed by biopharmaceutical companies Oxford BioMedica and Axovant Sciences. The trial will work with 30 participants living with Parkinson’s at hospitals in London and Cambridge, UK and Paris, France. The first stage will evaluate the safety and dosage of the therapy – and the second stage will assess the long-term effects of the therapy on motor function. Professor Thomas Foltynie, neurology consultant at University College London Hospitals – which is carrying out the research alongside University College London – said: “Genes that increase the production of dopamine could help alleviate the symptoms of Parkinson’s disease, potentially with fewer side effects than traditional drug treatments, by targeting only the areas of the brain that are lacking in dopamine.”
Pfizer launches new biopharmaceutical company to develop Parkinson’s drugs
Pharmaceutical company Pfizer has teamed with investment firm Bain Capital to launch Cerevel Therapeutics – a biopharmaceutical company focused on developing drugs for Parkinson’s and other central nervous system conditions. The new company – which will receive US $350 million of investment from Bain Capital – will begin working on phase three clinical trials on a Parkinson’s drug designed to increase levels of dopamine in the brain. Cerevel will also continue to develop several of Pfizer’s drug programmes which closed earlier this year. Marco Baptista, director of research programmes at The Michael J Fox Foundation – which has partnered with Pfizer since 2010 – said: “This is welcome news for Parkinson’s patients and researchers. Pfizer had developed a diverse group of novel therapeutics for Parkinson’s disease, which are now going to get another chance at success. MJFF looks forward to partnering with Cerevel to support the advancement of these promising…
AI technology could diagnose Parkinson’s in less than three minutes
Chinese technology enterprise Tencent has partnered with UK healthcare company Medopad and the Centre of Excellence in Parkinson’s and Movement Disorders at Kings College Hospital, UK, to create artificial intelligence (AI) software that may be able to diagnose Parkinson’s in less than three minutes. The team trained the AI system by analysing video footage of people with Parkinson’s, and believes it will help doctors identify and diagnose the condition at a far earlier stage. In addition, it is hoped the test could be carried out remotely using smartphone technology. Dan Vahdat, CEO and Co-founder of Medopad, said: “Our partnership with Tencent comes from a shared vision to change the future of healthcare as we know it. “In combining Medopad’s medical expertise and Tencent’s technical capabilities, we hope to provide the technology needed to support clinicians to predict preventable complications for people with Parkinson’s disease.”